The Effects of an Endothelin-A Receptor Antagonist on Choroidal Circulation

Okayama Igakkai Zasshi (Journal of Okayama Medical Association)
doi 10.4044/joma1947.109.3-6_51
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Okayama Medical Association

Related search

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan

Clinical Pharmacokinetics
Pharmacology
2015English

Effects of NG-monomethyl-L-arginine on Choroidal Circulation

Okayama Igakkai Zasshi (Journal of Okayama Medical Association)
1995English

SB 209670, a Rationally Designed Potent Nonpeptide Endothelin Receptor Antagonist.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1994English

Endothelin-A Receptor Antagonist Mediated Vasodilatation Is Attenuated by Inhibition of Nitric Oxide Synthesis and by Endothelin-B Receptor Blockade

Circulation
Cardiovascular MedicinePhysiologyCardiology
1998English

Attenuation of Ischemic Liver Injury by a Non-Selective Endothelin Receptor Antagonist

Transplantation Proceedings
SurgeryTransplantation
1997English

The Effects of Ambrisentan, a Selective Endothelin ETA Receptor Antagonist for Vasogenic Edema After Traumatic Brain Injury in Mice

Proceedings for Annual Meeting of The Japanese Pharmacological Society
2020English

Differential Effects of BQ-123 Against Endothelin-1 and Endothelin-3 on the Rat Vas Deferens: Evidence for an Atypical Endothelin Receptor

British Journal of Pharmacology
Pharmacology
1993English

The Choroidal Circulation and Retinal Metabolism—An Overview

Eye
MedicineArtsSensory SystemsOphthalmologyHumanities
1990English

Effects of the Endothelin ETA-Receptor Antagonist FR139317 on Development of Hypertension and Cardiovascular Hypertrophy in Deoxycorticosterone Acetate-Salt Hypertensive Rats.

The Japanese Journal of Pharmacology
1996English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy